Search results for " treatment"

showing 10 items of 3424 documents

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Effects of DBS in parkinsonian patients depend on the structural integrity of frontal cortex

2017

AbstractWhile deep brain stimulation of the subthalamic nucleus (STN-DBS) has evolved to an evidence-based standard treatment for Parkinson’s disease (PD), the targeted cerebral networks are poorly described and no objective predictors for the postoperative clinical response exist. To elucidate the systemic mechanisms of DBS, we analysed cerebral grey matter properties using cortical thickness measurements and addressed the dependence of structural integrity on clinical outcome. Thirty one patients with idiopathic PD without dementia (23 males, age: 63.4 ± 9.3, Hoehn and Yahr: 3.5 ± 0.8) were selected for DBS treatment. The patients underwent whole-brain preoperative T1 MR-Imaging at 3 T. G…

0301 basic medicineMalemedicine.medical_specialtyDeep brain stimulationmedicine.medical_treatmentDeep Brain StimulationStimulationGrey matterMotor ActivityArticleWorkflow03 medical and health sciences0302 clinical medicineSubthalamic NucleusInternal medicinemedicineDementiaHumansAgedMultidisciplinarybusiness.industryStandard treatmentStructural integrityParkinson DiseaseMiddle Agedmedicine.diseaseMagnetic Resonance Imagingnervous system diseasesFrontal LobeSubthalamic nucleus030104 developmental biologymedicine.anatomical_structuresurgical procedures operativeTreatment OutcomeFrontal lobenervous systemCardiologyFemalebusinesstherapeutics030217 neurology & neurosurgeryScientific Reports
researchProduct

Emergent Uric Acid Treatment is Synergistic with Mechanical Recanalization in Improving Stroke Outcomes in Male and Female Rats.

2018

Preclinical and clinical studies support a promising, albeit not definitive, neuroprotective effect of emergent uric acid (UA) administration in ischemic stroke. We assessed the effects of UA in an ischemic stroke model relevant to the current treatment paradigm of mechanical thrombectomy within the STAIR/RIGOR recommendations. A cohort of male and female Wistar rats was subjected to ischemic stroke with mechanical recanalization under physiological monitoring. The effects of transient middle cerebral artery occlusion (tMCAO) with adjunctive UA (IV, 16 mg/kg) or vehicle treatment were assessed at 24 h and 7 days. Outcomes included neurofunctional impairment, brain infarct (TTC staining, MRI…

0301 basic medicineMalemedicine.medical_specialtyMechanical ThrombolysisBrain damageNeuroprotectionBrain Ischemia03 medical and health sciencesCresyl violetchemistry.chemical_compoundRandom Allocation0302 clinical medicineuric acidInternal medicineEdemamedicineischemic strokeAnimalsRats WistarStrokebusiness.industryGeneral Neurosciencerat modeladjunctive treatmentBrainRecovery of Functionmedicine.diseaseCombined Modality TherapyUric AcidStrokeDisease Models Animal030104 developmental biologyNeuroprotective AgentschemistrythrombectomyAdjunctive treatmentIschemic strokeCardiologyUric acidneuroprotectionFemalemedicine.symptombusiness030217 neurology & neurosurgeryNeuroscience
researchProduct

Acute and chronic nicotine exposures differentially affect central serotonin 2A receptor function : focus on the lateral habenula

2020

Nicotine addiction is a serious public health problem causing millions of deaths worldwide. Serotonin (5-hydroxytryptamine

0301 basic medicineMalenucleus accumbensdorsal raphe nucleusmedicine.medical_treatmentstriatumPharmacologySmoking cessationSettore BIO/09 - FisiologiaSerotonin -- Receptorslcsh:ChemistryNicotineRats Sprague-DawleyNicotine addiction -- Treatment0302 clinical medicine5-HT2Asubstantia nigra pars compactaReceptor Serotonin 5-HT2Adentate gyruslcsh:QH301-705.5Spectroscopymedia_commonNeuronsGeneral MedicineDorsal raphe nucleu5-HT<sub>2C</sub>RComputer Science ApplicationsVentral tegmental areamedicine.anatomical_structuredepressionaddiction5-HT2CR; Addiction; Dentate gyrus; Depression; Dorsal raphe nucleus; Medial prefrontal cortex; Nucleus accumbens; Striatum; Substantia nigra pars compacta; Ventral tegmental area; Animals; Habenula; Male; Neurons; Nicotine; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2A; SerotoninReceptormedicine.drugAgonistNicotineSerotoninmedicine.drug_classmedia_common.quotation_subjectCentral nervous systemventral tegmental area substantia nigra pars compactaventral tegmental areaNucleus accumbensDentate gyruCatalysisArticleInorganic Chemistry03 medical and health sciencesmental disordersmedicineAnimalsNucleus accumbenPhysical and Theoretical ChemistryMolecular BiologyHabenulabusiness.industryAddictionOrganic ChemistryRats5-HT2CR030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Smoking cessationSprague-DawleySerotoninbusinessReceptors Serotonin 5-HT2030217 neurology & neurosurgerymedial prefrontal cortex
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. &lt; 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

2017

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML…

0301 basic medicineMedicine (miscellaneous)PharmacologyEngineered exosomeExosomesInterleukin 3Antineoplastic AgentMiceHEK293 Cellhemic and lymphatic diseasesDrug CarrierPharmacology Toxicology and Pharmaceutics (miscellaneous)Drug CarriersChronic myeloid leukemiaMyeloid leukemiaChronic myeloid leukemia; Drug delivery; Drug resistance; Engineered exosomes; Interleukin 3; Animals; Antineoplastic Agents; Cell Line Tumor; Cell Proliferation; Disease Models Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia Myelogenous Chronic BCR-ABL Positive; Mice; Receptors Interleukin-3; Treatment Outcome3. Good healthTreatment OutcomeImatinib MesylateHeterograftsHeterograftResearch Papermedicine.drugHumanEngineered exosomesAntineoplastic Agents03 medical and health sciencesIn vivoCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineAnimalsHumansneoplasmsInterleukin 3.Interleukin 3Cell Proliferationbusiness.industryAnimalImatinibmedicine.diseaseMicrovesiclesReceptors Interleukin-3ExosomeDisease Models AnimalHEK293 Cells030104 developmental biologyImatinib mesylateDrug resistanceCancer cellDrug deliverybusinessChronic myelogenous leukemia
researchProduct

Mitochondrial Changes in β0-Thalassemia/Hb E Disease.

2015

The compound β°-thalassemia/Hb E hemoglobinopathy is characterized by an unusually large range of presentation from essentially asymptomatic to a severe transfusion dependent state. While a number of factors are known that moderate presentation, these factors do not account for the full spectrum of presentation. Mitochondria are subcellular organelles that are pivotal in a number of cellular processes including oxidative phosphorylation and apoptosis. A mitochondrial protein enriched proteome was determined and validated from erythroblasts from normal controls and β°-thalassemia/Hb E patients of different severities. Mitochondria were evaluated through the use of mitotracker staining, analy…

0301 basic medicineMetabolic ProcessesErythroblastsProteomeProteomesCelllcsh:MedicineGene ExpressionAntigens CD34ApoptosisMitochondrionBiochemistryOxidative Phosphorylation0302 clinical medicineAnimal Cellshemic and lymphatic diseasesRed Blood CellsGene expressionlcsh:ScienceErythroid Precursor CellsEnergy-Producing OrganellesErythroid Precursor CellsStainingMultidisciplinaryCell DeathHemoglobin ECell StainingCell biologyGlobinsMitochondriamedicine.anatomical_structureCell Processes030220 oncology & carcinogenesisCellular Structures and OrganellesCellular TypesResearch ArticleMitochondrial DNAPrecursor CellsBone Marrow CellsOxidative phosphorylationBiologyBioenergeticsResearch and Analysis Methods03 medical and health sciencesmedicineHumansGlobinBlood Cellslcsh:Rbeta-ThalassemiaBiology and Life SciencesProteinsCell BiologyMolecular biologyChaperone ProteinsHemoglobinopathies030104 developmental biologyMetabolismApoptosisSpecimen Preparation and TreatmentCase-Control Studieslcsh:QPloS one
researchProduct

What happens in hospitals does not stay in hospitals: antibiotic-resistant bacteria in hospital wastewater systems.

2016

Hospitals are hotspots for antimicrobial-resistant bacteria (ARB) and play a major role in both their emergence and spread. Large numbers of these ARB will be ejected from hospitals via wastewater systems. In this review, we present quantitative and qualitative data of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, vancomycin-resistant enterococci and Pseudomonas aeruginosa in hospital wastewaters compared to community wastewaters. We also discuss the fate of these ARB in wastewater treatment plants and in the downstream environment. Published studies have shown that hospital effluents contain ARB, the burden of these bacteria being dependent on their local prevalence. The…

0301 basic medicineMicrobiology (medical)030106 microbiologyWastewater010501 environmental sciencesurologic and male genital diseasesmedicine.disease_cause01 natural sciencesbeta-LactamasesVancomycin-Resistant EnterococciWater Purification03 medical and health sciencesAntibiotic resistance[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance BacterialEscherichia colimedicineHumansVancomycin-resistant EnterococcusSelection GeneticEffluentComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciencesPseudomonas aeruginosabusiness.industryGeneral MedicineAntimicrobialHospitals6. Clean waterAnti-Bacterial Agents3. Good healthBiotechnologyMultiple drug resistanceInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyWastewater13. Climate actionPseudomonas aeruginosaSewage treatmentbusiness
researchProduct

The clinical impact of PCR‐based point‐of‐care diagnostic in respiratory tract infections in children

2020

Abstract Background Children are commonly affected by respiratory tract infections. Based on clinical symptoms, laboratory evaluation, and imaging, the causative pathogen often cannot be delineated. Point‐of‐care‐testing systems that provide an opportunity for fast detection of common viruses and some bacteria can therefore influence treatment's options. We aimed to examine whether the Biofire® FilmArray® has an effect on antibiotic treatment, duration of antibiotic therapy, and length of hospital stay within a pediatric cohort. Methods We included children who were admitted to inpatient treatment with an acute respiratory tract infection from 02/2017 to 04/2018 using the FA respiratory pan…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyPathogen detectionAdolescentmedicine.drug_classPoint-of-care testingPoint-of-Care SystemsAntibioticsClinical BiochemistryAdenovirus Infections Human03 medical and health sciences0302 clinical medicineInternal medicinepoint‐of‐care‐testingMedicineImmunology and AllergyHumansChildAcute respiratory tract infectionRespiratory Tract InfectionsResearch ArticlesPoint of careBiochemistry medicalPast medical historyRespiratory tract infectionsbusiness.industryBiofire® FilmArray®acute respiratory tract infectionsBiochemistry (medical)Public Health Environmental and Occupational HealthInfantHematologyLength of StayAnti-Bacterial AgentsMedical Laboratory Technology030104 developmental biology030220 oncology & carcinogenesisCase-Control StudiesChild PreschoolCohortantibiotic treatmentmultiplex RT‐PCRFemalebusinessMultiplex Polymerase Chain ReactionResearch ArticleJournal of Clinical Laboratory Analysis
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct